Blood pressure is correlated with vitamin d(3) serum levels in dialysis patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of low blood pressure and orthostatic hypotension, published as a clinical trial.

The blood pressure, the most influencing factor in cardiovascular disease in end-stage renal failure patients, follows a seasonal variation during the year.

Since vitamin D(3) is known to be related to sun exposure, the researchers wanted to evaluate the putative participation of the vitamin D(3) metabolism in blood pressure modifications.

Who Took Part

The abstract describes 22 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Supine systolic and diastolic blood pressures were measured before every dialysis session (>12,000 measurements) and the intact parathormone (iPTH), 25-hydroxyvitamin D(3) [25(OH)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] levels every 3 months (>300 determinations).

The mean values of blood pressure per season and per patient were taken for analysis using a 4-year longitudinal study design.

What Was Measured

The subject headings attached to it are Blood Pressure, Calcifediol, Calcitriol, Cholecalciferol, Kidney Failure, Chronic, Longitudinal Studies and Parathyroid Hormone.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 22 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Blood purification), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Low blood pressure and orthostatic hypotension research.